By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported no revenues for its second quarter, down from $800,000 a year ago.

The company's revenues comprise mainly of research fees and milestone and do not include government grants, which Compugen records as a reduction of R&D costs.

For the three months ended June 30, net loss totaled $2.2 million, or $.06 per share, up 146 percent from a net loss of $896,000, or $.03 per share a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.

Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.

Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.

In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.